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A B S T R A C T
3D8 single-chain Fv (scFv) is a catalytic nucleic acid antibody with anti-viral activity against a broad
spectrum of viruses. Here we investigated the functional stability of 3D8 scFv to provide a basis for
engineering a 3D8 scFv derivative and for developing stable formulations with improved stability and
potential use as an anti-viral agent. The stability of 3D8 scFv was assessed by measuring its DNA-
hydrolyzing activity under different biochemical and physical conditions using a ﬂuorescence resonance
energy transfer (FRET)-based method. In addition, the anti-inﬂuenza (H9N2) effect of 3D8 scFv was
evaluated in A549 cells. 3D8 scFv was stable at 50 C for 6 h at pH 7.2, for 3 days at pH 4–10 at 37 C and
30 days at pH 4–8 at 37 C. The stability was not affected by a reducing condition, freeze–thawing for
up to 30 cycles, or lyophilization. Evaluation of the anti-virus effect showed that cells treated with
32–128 units of 3D8 scFv showed a 50% decrease in inﬂuenza replication compared to untreated cells.
Based on its enzymatic stability in various biochemical and physical environments, 3D8 scFv holds good
potential for development as an anti-viral therapeutic.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The stability of antibodies is a prerequisite for their use in
pharmaceutical and non-pharmaceutical applications. The bio-
physical stability of antibodies varies, making the development of
antibody pharmaceuticals a complicated process. Antibody insta-
bility, which eventually leads to the loss or reduction of antibody
activity, can be a result of multiple routes of degradation that
occurs during bioprocessing, and is a major challenge in the
manufacturing and development of antibody-based therapeutics.
Routes of degradation involve one or more of pathways by physical
instability including denaturation and aggregation, and by
chemical instability including deamidation, oxidation, proteolysis,
b-elimination, and interchange of disulﬁde bonds. Accordingly,
factors affecting the biophysical stability of numerous antibodies
have been elucidated, and many methods to increase their stability* Correspondence author at: Department of Microbiology, Ajou University School
of Medicine, 206 World Cup-ro, Yeongtong-gu, Suwon 443-749, Republic of Korea.
Fax: +82 31 219 5079.
E-mail address: kwonmh@ajou.ac.kr (M.-H. Kwon).
http://dx.doi.org/10.1016/j.ijpharm.2015.10.076
0378-5173/ã 2015 The Authors. Published by Elsevier B.V. This is an open access article unhave been successfully developed (Edwardraja et al., 2011; Liu
and May, 2012; Nieba et al., 1997; Wang et al., 2007; Worn and
Pluckthun, 2001).
Single chain Fv fragment (scFv) is a 27 kDa recombinant
antibody structure in which the variable domains (VH and VL) from
the heavy and light chains of an antibody are connected by a
ﬂexible peptide linker. ScFvs are commonly used for basic research
and biotechnical and medicinal applications. They provide
advantages such as rapid design and characterization, production
using various expression systems (bacteria, yeast, plant, and
animal cells), compatibility with phage display techniques, and a
straightforward platform for antibody engineering to improve
stability and function. Promising scFvs are converted into whole
IgG, IgE, or scFv-Fc formats to increase their stability and efﬁcacy in
various physiological environments (Boel et al., 2000; Braren et al.,
2007; Gould et al., 2005). Alternatively, scFvs may be used as is in
basic biotechnology and pharmaceutical applications.
3D8 scFv is a catalytic antibody with nucleic acid-binding and
-hydrolyzing activities that undergoes cellular internalization.
Attention has been given to 3D8 scFv due to its anti-viral effect
against a broad spectrum of viruses. The anti-viral activity of
3D8 scFv was demonstrated in vitro (Joung et al., 2012; Jun et al.,der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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such as classical swine fever virus (CSFV) (Jun et al., 2010),
vesicular stomatitis virus (VSV) (Joung et al., 2012; Jun et al., 2010),
and human herpes simplex virus-1 (HSV-1) (Lee et al., 2014), as
well as against a variety of plant viruses (Lee et al., 2013a,b). Most
recently, the possibility of developing preventive anti-viral pro-
biotics was demonstrated by generating a transgenic Lactobacillus
that secretes 3D8 scFv that protected mice against infection by
gastrointestinal murine norovirus (Hoang et al., 2015). The
mechanism of action of the anti-viral effect of 3D8 scFv is believed
to be due to its ability to hydrolyze the nucleic acids (the genome
and/or transcripts) of invading viruses during the early phase of
infection.
The fact that 3D8 scFv protects the host from multifarious
viruses regardless of genomic composition makes 3D8 scFv a
candidate for potential application as an anti-viral agent. However,
the stability of 3D8 scFv has not been intensively studied. In this
study, we assessed the functional stability of 3D8 scFv by
determining its DNA-hydrolyzing and/or DNA-binding activities
under conditions of varying temperature, pH, storage period,
freeze–thaw cycles, and reducing environment. We also evaluated
the anti-virus effect of 3D8 scFv against inﬂuenza, and established
a unit of activity deﬁned as a measure of its DNA-hydrolyzing
activity, which mediates its anti-virus effect. The data we obtained
may be used to facilitate future potential development for
application in targeting a broad spectrum of viral pathogens,
including inﬂuenza.
2. Materials and methods
2.1. Preparation of scFv proteins
The pIg20-scFv expression vector, in which VH and VL are
connected by a (Gly4/Ser1)3 linker following a Pho A leader signal
sequence, was used to express scFv proteins with a protein A tag
(7 kDa) at the C-terminus. ScFv proteins were expressed in
Escherichia coli BL21(DE3) pLysE cells (Novagen) and puriﬁed
from bacterial culture supernatants in a soluble form by IgG-
SepharoseTM 6 Fast Flow column (GE Healthcare) chromatography
(Kim et al., 2006). The concentrations of 3D8 scFv proteins
(mg ml1 cm1) were determined by the extinction coefﬁcients at
280 nm, which were calculated from the respective amino acid
sequences.
2.2. Enzyme-linked immunosorbent assay (ELISA)
To assay the effect of temperature on the DNA-binding activity
of 3D8 scFv, 3D8 scFv (2 mg/ml in PBS) was incubated at various
temperatures (20–100 C) for 2 h or 6 h, and the proteins were then
loaded into 96-well polystyrene plates coated with pUC57 plasmid
DNA (1 mg/ml). The proteins bound the wells were detected using
rabbit IgG (Sigma), followed by alkaline phosphatase (AP)-
conjugated anti-rabbit IgG (Pierce Biotechnology), as described
previously (Kim et al., 2006). Finally, absorbance of the wells was
read at 405 nm in a microplate reader. Each incubation step was
performed in TBS (50 mM Tris–Cl, pH 7.2, and 50 mM NaCl)
containing 3% bovine serum albumin (BSA) for 1 h at room
temperature (RT), followed by three washes with TBS containing
0.05% Tween 20.
To assess the effect of temperature, pH, and reducing conditions
on the DNA-binding activity of 3D8 scFv, proteins were processed
in an assay-dependent manner before they were loaded into the
96-well plate containing DNA antigen. To assay the DNA-binding
activity of 3D8 scFv at various pH values, 3D8 scFv dissolved in PBS
(10 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl, and 137 mM NaCl, pH
7.2) was dialyzed against the universal buffers (50 mM Tris–HCl,20 mM sodium acetate, and 20 mM MES) at pH values ranging from
3 to 12 (McAuley et al., 2008). To assay the DNA-binding activity
under reducing conditions, the reducing reagent dithiothreitol
(DTT) was added to 3D8 scFv (2 mg/ml in PBS) at a ﬁnal
concentration of 1 mM.
2.3. Fluorescence resonance energy transfer (FRET)-based DNA
cleavage assay
A DNA substrate comprising 21 nucleotides labeled with 6-
carboxyﬂuorescein (FAM) at the 50-terminus and a black hole
quencher (BHQ) at the 30-terminus (50-FAM-CGATGAGTGCCATG-
GATATAC-BHQ-30) was generated by M-Biotech. 3D8 scFv (100 ml,
ﬁnal concentration of 250 nM), or 1 U DNase I (New England
Biolabs), was loaded into the wells of a 96-black-well plate
containing 100 ml of DNA substrate (ﬁnal concentration of
250 nM). Immediately after addition to the DNA substrate, the
ﬂuorescence intensity was read in real time over a period of
6 h at 37 C in a ﬂuorescence detector (Molecular Devices).
Each reaction was brought to a ﬁnal volume of 200 ml with TBS-
Mg buffer (100 mM Tris–HCl, 150 mM NaCl, 0.05% Tween 20,
and 2 mM MgCl2, pH 7.4). The DNase I reaction was carried out
in DNase I buffer (10 mM Tris–HCl, 2.5 mM MgCl2, and 0.5 mM
CaCl2, pH 7.6).
To assess the effects of temperature and pH on the DNA-
hydrolyzing activity of scFv, proteins were processed in an assay-
dependent manner before being loaded into the 96-black-well
plate containing DNA substrate. To assess the effects of tempera-
ture on the DNA-hydrolyzing activity, proteins (5 mg/ml stock
concentration) dissolved in PBS were pre-incubated for 2 h or 6 h at
each temperature. To assay the stability of the DNA-hydrolyzing
activity of 3D8 scFv at different pHs, 3D8 scFv (stock of 5 mg/ml)
was pre-incubated for 2 h–30 days at 37 C in universal buffer with
pH values ranging from pH 3 to 12, and then dialyzed against TBS-
Mg buffer to return it to pH 7.4. To assess the DNA-hydrolyzing
activity under reducing conditions, DTT was added to 250 nM
3D8 scFv in TBS or 1 U DNase I in DNase I buffer (New England
Biolabs) at a ﬁnal concentration of 1 mM.
In the experimental setting to determine the unit of DNA-
hydrolyzing activity of 3D8 scFv, either 3D8 scFv at various
concentrations (0–2 mM) was incubated with 250 nM DNA
substrate in TBS-Mg buffer, or 250 nM 3D8 scFv was incubated
with various concentrations of DNA substrate (0–1 mM).
2.4. Agarose gel electrophoresis-based DNA cleavage assay
To assay the DNA-hydrolyzing activity of 3D8 scFv at various pH
values, 3D8 scFv (250 nM) or 1 U DNase I was incubated for 3 h at
37 C with 400 ng of 1 kb linear DNA (a PCR product) as a substrate
in universal buffer at pH 3–12 or DNase I-speciﬁc buffer,
respectively. The reaction mixture was separated on a 1% agarose
gel, followed by staining with Ribogreen (Invitrogen). To determine
the unit of 3D8 scFv activity, 3D8 scFv dissolved in TBS-Mg buffer
(pH 7.4) at different concentrations (two-fold diluted from 250 nM)
was incubated for 3 h at 37 C with 400 ng of 1 kb linear DNA
substrate, followed by electrophoresis on a 1% agarose gel and
staining with Ribogreen.
2.5. Freeze–thaw and lyophilization
To assess the effect of multiple freeze–thaw cycles on 3D8 scFv
stability, aliquots of 3D8 scFv dissolved in PBS (pH 7.2) at 5 mg/ml
were frozen at 70 C for 2 h and then thawed at room temperature
for 1 h. This was repeated for up to 30 cycles. To assess the effect of
lyophilization on 3D8 scFv stability, a 100 ml aliquot of 3D8 scFv
dissolved in PBS (pH 7.2) at 5 mg/ml was lyophilized. The
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used in a DNA-hydrolysis assay.
2.6. Preparation of inﬂuenza H9N2 virus
The low pathogenic avian inﬂuenza H9N2 (A/Chicken/Korea/
MS96/96) virus (Kwon et al., 2010) was kindly provided by the
National Veterinary Research and Quarantine Service (NVRQS) in
Korea. The virus was propagated using pathogen-free fertilized
eggs (Kwon et al., 2010). Since low pathogenic inﬂuenza
H9N2 exhibits very weak plaque-forming capacity, titer was not
determined by direct plaque-forming assay. Instead, the titer of
virus stock that is expressed as 50% tissue culture infection dose
per ml (TCID50/ml) was determined by an end-point method in
which infection with ﬁve-fold serial dilutions was performed in
96-well plates using A549 human lung epithelial cells. The plaque-
forming units (PFU) were then estimated by multiplying the
TCID50 by 0.7 (Daelemans et al., 2011).
2.7. Establishment of an A549 cell line stably expressing 3D8 scFv
A549 cells were transfected with plasmid pJHCa-3D8 scFv using
Lipofectamine 2000 transfection reagent (Invitrogen), according toFig. 1. Effect of temperature on the DNA-hydrolyzing and -binding activities of 3D8 scFv. 
assay. (A) FRET-based DNA cleavage assay. Pre-incubated 3D8 scFv (250 nM) was reac
measured in real time for 360 min at 37 C. (B) Protein integrity after incubation at 40 C,
Coomassie staining. 3D8 scFv stored at -20 C was used as the control. (C) ELISA for DN
coated with pUC57 plasmid DNA (1 mg/ml). The bound 3D8 scFv was detected with ra
negative control. Data are representative of two independent experiments performed ithe manufacturer’s instructions. G418-resistant A549 cells were
selected by maintaining the cells for 2 weeks in 10% FBS-DMEM
supplemented with 1 mg/ml of G418 (Sigma). Limiting dilutions of
G418-resistant A549 cells were performed twice to establish
homogenous single clones. The expression of 3D8 scFv in the
selected clones was conﬁrmed by Western blot using a rabbit
anti-3D8 scFv antibody.
2.8. Immunoﬂuorescence assay
Suppression of inﬂuenza (H9N2) replication by exogenous
3D8 scFv treatment was assessed by immunoﬂuorescence assay.
A549 cells seeded at a density of 3.5 105 cells/well in a 6-well
culture plate were incubated with various amounts of 3D8 scFv in
serum-free TOM media (Invitrogen) for 6 h at 37 C. The cells were
then further incubated in complete medium (DMEM with 10% FBS,
100 units/ml penicillin, and 100 mg/ml streptomycin) for 18 h at
37 C under 5% CO2. For subsequent H9N2 virus infection (Kim
et al., 2012), culture medium was removed and the cells were
incubated with the virus in infection medium (PBS containing 0.3%
BSA, 1 mM MgCl2, 0.9 mM CaCl2, 100 units/ml penicillin, 100 mg/ml
streptomycin, and 2 mg/ml trypsin) at an MOI (multiplicity of
infection) of 1 for 1 h at 37 C under 5% CO2. After removal of the3D8 scFv was pre-incubated for 2 h or 6 h at the speciﬁed temperatures prior to each
ted with a dual-labeled DNA substrate (250 nM), and ﬂuorescence intensity was
 60 C, and 100 C for 6 h was assessed by SDS-PAGE of 10 mg of protein, followed by
A-binding activity. Pre-incubated 3D8 scFv (2 mg/ml) was added to a 96-well plate
bbit IgG, followed by AP-conjugated goat anti-rabbit IgG. HW6 scFv was used as a
n triplicate.
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complete medium for 17 h at 37 C under 5% CO2. At 18 h post-
infection, cells were suspended by trypsinization, washed
once with cold PBS buffer (50 mM sodium phosphate and
100 mM NaCl, pH 7.2) containing 2% FBS, and ﬁxed using 4%
paraformaldehyde in PBS for 20 min at room temperature. After
permeabilization of the cell membranes with Perm-buffer (1% BSA,
0.1% saponine, and 0.1% sodium azide in PBS) for 1 h at 4 C, cells
were immunostained with a 1/100 dilution of anti-NP2 (nucleo-
protein 2) antibody (Santa Cruz Biotechnology) and then a
1/100 dilution of FITC-labeled anti-mouse IgG (Abcam). Following
incubation with antibodies, cells were washed three times
with 3 ml of ice-cold PBS and suspended in 0.5 ml of 2%
paraformaldehyde in PBS. Cells were analyzed by ﬂow cytometry
using a Becton Dickinson FACSCalibur.
Suppression of inﬂuenza (H9N2) replication in AG11 cells,
which are the A549 cells stably expressing 3D8 scFv, was assessed
by immunoﬂuorescence assay as described above. Brieﬂy, culture
medium was removed, and the cells were incubated with the virus
in infection medium at an MOI of 1 for 1 h at 37 C. After removal of
the infection medium, the cells were further incubated in fresh
complete medium for 17 h at 37 C. At 18 h post-infection, cells
were washed, ﬁxed, and permeabilized, followed by staining with
anti-NP2 antibody and FITC-labeled anti-mouse IgG for ﬂow
cytometry.
3. Results
3.1. Effect of temperature on the DNA-binding and -hydrolyzing
activity of 3D8 scFv
The effect of temperature on the DNA-hydrolyzing activity of
3D8 scFv was analyzed at pH 7.2 using a FRET-based DNA cleavage
assay in which the hydrolysis of a DNA substrate double-labeled
with a ﬂuorophore at the 50-terminus and its quencher at the 30-
terminus was measured according to the increase in ﬂuorescence
intensity. DNase I and HW6 scFv (anti-human DR5 antibody) were
used as positive and negative controls, respectively. No decrease in
activity was observed after 6 h at temperatures up to 50 C, while
activity was signiﬁcantly reduced by 30% and 90% after 2 h or
6 h, respectively, at temperatures 60 C and higher, and completely
lost after 2 h at temperatures over 70 C (Fig. 1A). Thus, 3D8 scFv is
stable for at least 6 h at temperatures of up to 50 C at pH 7.2.
Aggregation of 3D8 scFv was slightly increased at elevated
temperatures (Fig. 1B), but no visible degradation was detected,
indicating that the loss of 3D8 scFv activity could be due to at leastFig. 2. Proﬁle of the effect of pH on DNA-hydrolyzing and -binding activities of 3D8 scFv. (
various pHs was reacted with linear DNA (400 ng) 1000 bp in length at 37 C for 2 h at p
representative of two independent experiments. (B) pH-dependent DNA-binding activity
with pUC57 plasmid DNA (1 mg/ml). DNA binding was detected by incubating the sample
mean  S.D. of two independent experiments performed in triplicate.partly due to protein aggregation. The instability of 3D8 scFv at
elevated temperatures could also be due to chemical alterations,
such as deamidation or oxidation, which cannot be detected by
SDS-PAGE analysis.
To analyze the effect of temperature on the stability of the
DNA-binding activity of 3D8 scFv, an ELISA was performed with
3D8 scFv that had been exposed to different temperatures for 2 h
or 6 h. Compared to incubation at 20 C, 3D8 scFv retained
approximately 50% of its DNA-binding activity after incubation at
50 C for 2 h or 6 h, and complete loss when exposed to
temperatures over 60 C for 2 h or 6 h (Fig. 1C). HW6 scFv did
not show any DNA-binding activity, regardless of exposure
temperature or time.
3.2. Effect of pH on the DNA-binding and -hydrolyzing activity of 3D8
scFv
The DNA-binding and -hydrolyzing activities of 3D8 scFv at each
pH were analyzed by reacting 3D8 scFv with DNA under various
pH-buffered conditions at 23 C. DNA hydrolysis was assessed by
gel electrophoresis of the reaction mixture, instead of FRET-based
assay, because the ﬂuorescein conjugated to the nucleotide
substrate is sensitive to solution pH, leading to analytical errors
(Zhu et al., 2005). DNA-hydrolysis activity reached a maximum at a
range of pH 7–11, whereas no activity was observed at pH 3–5 or 12
(Fig. 2A). The DNA-binding activity of 3D8 scFv showed the same
pattern as that of the DNA-hydrolyzing activity of 3D8 scFv with
respect to pH conditions (Fig. 2B).
3.3. Functional stability of 3D8 scFv after exposure to different pHs for
different periods
To analyze the stability of the DNA-hydrolyzing activity if
3D8 scFv under various pH conditions in universal buffer at 37 C,
FRET-based DNA cleavage assay was performed with 3D8 scFv
protein at a concentration of 5 mg/ml that had been exposed to pHs
ranging from 3 to 12 and then dialyzed against TBS-Mg buffer (pH
7.2). No signiﬁcant change in the DNA-hydrolyzing activity
following incubation for up to 12 h at any pH was observed,
except at pH 12, at which point the activity was completely lost. A
reduction of 50% was observed after 3 days at pH 11. After 7 days,
complete loss of activity at pH 11 and a signiﬁcant reduction in
activity at pH 3 and 10 were observed. The activity was retained
after 14 days at pH 4–9 at 37 C and for 30 days at pH 4–8 at 37 C.
(Fig. 3A). HW6 scFv exhibited no DNA-hydrolysis activity (Fig. 3B).
SDS-PAGE and Coomassie staining of 3D8 scFv incubated at pH 3, 6,A) pH dependence of the DNA-hydrolyzing activity of 3D8 scFv. 3D8 scFv (250 nM) at
H 7.2. The reaction mixture was then electrophoresed on a 1% agarose gel. Data are
 of 3D8 scFv. 3D8 scFv (2 mg/ml) at various pHs was added to a 96-well plate coated
s with rabbit IgG, followed by AP-conjugated goat anti-rabbit IgG. Data represent the
Fig. 3. Functional stability of 3D8 scFv at various pHs. After exposure to pHs ranging from 3 to 12 at 37 C for various periods (2 h–30 days, as indicated), 3D8 scFv was returned
to a buffer with pH 7.2. (A) The DNA-hydrolyzing activity of 3D8 scFv was measured by FRET-based DNA cleavage assay. Data are representative of two independent
experiments performed in triplicate. (B) The DNA-hydrolyzing activity of control HW6 scFv incubated at pH 3, 6, or 11 for 2 h at 37 C was measured. (C) Protein integrity was
assessed by SDS-PAGE and subsequent Coomassie staining of representative aliquots (10 mg each) of 3D8 scFv incubated at pH 3, 6, or 11 at 37 C for 7 days. 3D8 scFv in PBS (pH
7.4) at 20 C was used as the control.
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these samples, in contrast to control 3D8 scFv that was stored at
20 C in TBS at pH 7.2 (Fig. 3C). Interestingly, a discrepancy
between the extent of degradation and the degree of reduction in
activity was observed. This suggests that the reduction in DNA-
hydrolyzing activity is not exclusively due to protein degradation,
but possibly also due to subvisible levels of aggregation or chemical
alterations.
3.4. Effect of freeze–thaw cycles and lyophilization on functional
stability
The effect of freezing at 70 C and subsequent thawing of
3D8 scFv solution at a concentration of 5 mg/ml in PBS buffer (pH
7.2) on the stability of the antibody was evaluated by measuring
DNA-hydrolyzing activity. 3D8 scFv was stable for up to 30 freeze–
thaw cycles (Fig. 4A), and following lyophilization and reconstitu-
tion (Fig. 4B). No signiﬁcant protein degradation was observed in
the samples following freeze–thawing (Fig. 4C) or lyophilization
(Fig. 4D) compared to the control samples.
3.5. Stability of 3D8 scFv activity under reducing conditions
The DNA-binding and -hydrolyzing activities of 3D8 scFv under
reducing conditions was investigated with ELISA and FRET-based
hydrolysis assays, respectively, in the presence or absence of 1 mM
DTT. Neither the DNA-hydrolyzing (Fig. 5A) nor DNA-binding
activities (Fig. 5B) of 3D8 scFv were affected by the presence of DTT,
suggesting that 3D8 scFv maintains a stable structure without
intra-disulﬁde bonds. DNase I used as a positive control showed
full activity in the presence of DTT. This is because reduced DNase I
is inactive, but can be reactivated in the presence of the Ca2+ or Mg2
+ that is included in the provided DNase I buffer (New England
Biolabs website).Fig. 4. Functional stability of 3D8 scFv following lyophilization and multiple freeze–thaw
water. DNA-hydrolysis activity was then determined by FRET-based DNA cleavage assay
freeze–thawing. The control sample was stored at 20 C. Data in (A) and (B) are repr
integrity after lyophilization (C) and multiple freeze–thaw cycles (D) was assessed by SDS
used for the control.3.6. Unit determination for the DNA-hydrolysis activity of 3D8 scFv
To establish a quantitative assay method for assessing the anti-
viral effect of 3D8 scFv, the unit for the DNA-hydrolyzing activity of
3D8 scFv needed to be deﬁned. To establish this, we performed a
FRET-based DNA-hydrolysis assay. When a series of two-fold
dilutions of 3D8 scFv were incubated with 250 nM DNA substrate,
complete DNA hydrolysis was observed in 3 h at concentrations
greater than 250 nM 3D8 scFv (Fig. 6A). The amount of DNA in
100 ml of 250 nM substrate solution was calculated to be 400 ng,
and the amount of scFv in 100 ml of 250 nM scFv solution was
calculated to be 2 mg. Thus, we deﬁned the unit as follows: one unit
is the minimum amount of 3D8 scFv necessary to completely
degrade 400 ng of a 21-base length nucleotide (50-CGATGAGTGC-
CATGGATATAC-30) in 3 h at 37 C in TBS-Mg buffer. Therefore, one
unit of 3D8 scFv is 2 mg. Furthermore, we conﬁrmed the relevance
of the unit determination by performing a DNA-hydrolysis assay in
which one unit of 3D8 scFv was incubated with various amounts of
the 21-base length nucleotide. The results showed that 400 ng of
the nucleotide was completely degraded by one unit of 3D8 scFv in
3 h, while 800 ng of nucleotide was not (Fig. 6B), indicating that the
deﬁnition of one unit is reasonable. The results shown in Fig. 6A
were compared with the results of an agarose gel electrophoresis-
based DNA cleavage assay in which two-fold dilutions of 3D8 scFv
were incubated with 400 ng of a 1000 bp-sized PCR product for 3 h.
Complete hydrolysis of the 1000 bp DNA substrate by 250 nM
3D8 scFv was observed in 3 h (Fig. 6C), corresponding to the results
of the FRET-based DNA cleavage assay, despite the differences in
the DNA substrates and assay readout.
3.7. Anti-viral activity of 3D8 scFv
Since the puriﬁed 3D8 scFv protein is able to penetrate cell
membrane by itself and exert anti-viral activity (Jun et al., 2010), cycles. (A) 3D8 scFv (5 mg/ml) in PBS was lyophilized and then dissolved in distilled
. (B) A 1 ml aliquot of 3D8 scFv (5 mg/ml) in PBS was subjected to up to 30 cycles of
esentative of two independent experiments performed in triplicate. (C, D) Protein
-PAGE of 10 mg protein, followed by Coomassie staining. Unprocessed 3D8 scFv was
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Fig. 5. Functional stability of 3D8 scFv under reducing conditions. The DNA-hydrolyzing and -binding activities of 3D8 scFv under reducing conditions were assessed by FRET-
based DNA-hydrolysis assay and ELISA. (A) 3D8 scFv (250 nM) was reacted with a dual-labeled DNA substrate (250 nM) in the presence or absence of 1 mM DTT. The
ﬂuorescence intensity was then measured in real time for 360 min at 37 C. DNase I (1 U) was used as a control for the reaction. Data are representative of two independent
experiments performed in triplicate. (B) 3D8 scFv (2 mg/ml) was added to a 96-well plate coated with pUC57 plasmid DNA (1 mg/ml) in the presence or absence of 1 mM DTT.
The bound 3D8 scFv was detected by incubation with rabbit IgG, followed by AP-conjugated goat anti-rabbit IgG. Data represent the mean  S.D. of two independent
experiments performed in triplicate.
Fig. 6. Determination of the unit of 3D8 scFv DNA-hydrolysis activity. The DNA-hydrolyzing activity of 3D8 scFv was measured to establish a unit of measure. (A, B) FRET-
based DNA-hydrolysis assays. Either a ﬁxed amount (400 ng) of dual-labeled DNA substrate was mixed with various concentrations of 3D8 scFv (A), or a ﬁxed amount (one
unit) of 3D8 scFv was mixed with various concentrations of dual-labeled DNA substrate (B). DNase I (1 U) was used as a control. Data shown in (A) and (B) are representative of
two independent experiments performed in triplicate. (C) Agarose gel electrophoresis-based DNA-hydrolysis assay for comparison with the results of the FRET-based DNA-
hydrolysis assay shown in A. 3D8 scFv (250 nM) at different concentrations was reacted with linear DNA (400 ng), 1000 bp in length, at 37 C for 3 h at pH 7.2. The reaction
mixture was then electrophoresed on a 1% agarose gel. Data are representative of two independent experiments.
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infection in A549 cells. Cells were pretreated with various amounts
of 3D8 scFv protein for 24 h and then infected with inﬂuenza
(H9N2) at an MOI of 1.0. Virus replication was determined by ﬂow
cytometry at 18 h post-infection using mouse anti-inﬂuenza
nucleoprotein (NP) antibody. The cells were pretreated with
3D8 scFv for 24 h prior to virus infection to allow enough time for
3D8 scFv to be released into the cytosol, because it takes at least
12 h after cellular internalization for 3D8 scFv to reach the cytosol,
where it is functional for nucleic acid hydrolysis (Jang et al., 2009).
Compared to untreated cells, virus propagation was signiﬁ-
cantly reduced (48–52%) in the presence of 3D8 scFv at amountsgreater than 32 U. NP-positive cells were detected at levels of
30.2%, 31.0%, and 28.4% in inﬂuenza-exposed cells treated with
3D8 scFv at 32 U, 64 U, and 128 U, respectively, compared to
untreated inﬂuenza-exposed cells, 59.1% of which were positive for
NP (Fig. 7A and B). Under microscopic observation of the cells at
18 h post-infection, apoptotic cell death, which is a cytopathic
effect of inﬂuenza, was consistently observed in control A549 cells
but not in A549 cells pretreated with 32 units of 3D8 scFv (Fig. 7C).
Because the anti-viral activity of 3D8 scFv against inﬂuenza has not
yet been tested, we validated the anti-viral activity of 3D8 scFv
against inﬂuenza via intracellular expression of 3D8 scFv. To test
whether intracellular expression of 3D8 scFv protein is able to
Fig. 7. Anti-viral activity against inﬂuenza (H9N2). (A) Flow cytometry was performed to assess the correlation between the units of 3D8 scFv and anti-viral activity.
A549 cells (3.5 105 cells/well in 6-well culture plate) were treated with various units of 3D8 scFv protein for 24 h at 37 C, and then infected with inﬂuenza (H9N2) at an MOI
of 1 for 18 h. Cells were detached, ﬁxed, and permeabilized, followed by immunostaining with mouse anti-inﬂuenza NP antibody and then FITC-anti-mouse IgG antibody. Data
are expressed as the percentage of cells infected with virus compared with cells not treated with 3D8 scFv protein. The percentage of infected non-treated cells (positively-
stained cells) was arbitrarily set at 100%. HW6 scFv antibody (64 mg corresponding to 32 U 3D8 scFv) was used as a negative control. Data are representative of three
independent experiments. (B) Representative results of ﬂow cytometry of cells treated with 128 U 3D8 scFv. (C) Microscopic observation of the cytopathic effect in inﬂuenza-
infected cells. Cell death in inﬂuenza-infected cells at an MOI of 1 was observed by phase-contrast microscopy (magniﬁcation 40) at 18 h post-infection, with or without 24 h
of pretreatment with 32 units of 3D8 scFv. Data are representative of two independent experiments. (D) Flow cytometry to conﬁrm the anti-viral activity of 3D8 scFv in
AG11 cells, an A549 cell line stably expressing 3D8 scFv. Cells were infected with inﬂuenza (H9N2) at an MOI of 1 for 18 h, followed by immunostaining with mouse anti-
inﬂuenza NP antibody and then FITC-anti-mouse IgG antibody. Data are representative of three independent experiments. (E) Cytopathic effect (apoptotic cell death) induced
by inﬂuenza (H9N2) infection (MOI of 1) was observed by phase-contrast microscopy at 24 h post-infection (magniﬁcation 100).
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was determined in AG11 cells, an A549 cell line that stably
expresses 3D8 scFv. Flow cytometry at 18 h post-infection using
mouse anti-inﬂuenza NP antibody showed that NP-positive cells
were signiﬁcantly reduced (15.1%) in AG11 cells compared to
control A549 cells (66.5%) (Fig. 7D). These results demonstrate that
intracellular 3D8 scFv confers anti-viral activity against inﬂuenza.
When cell death in inﬂuenza (H9N2)-infected cells was observed
by phase-contrast microscopy at 24 h post-infection, AG11 cells
were shown to be considerably resistant to apoptotic cell death
compared to A549 cells (Fig. 7E).
4. Discussion
In this study, we analyzed the functional stability of the
catalytic antibody 3D8 scFv, which has both nucleic acid-binding
and -hydrolyzing activities. To do this, we assessed the functional
stability of 3D8 scFv by measuring its DNA-hydrolyzing activityunder various physical and chemical conditions, rather than
assessing the structural changes of the protein. That is, we
considered the DNA-hydrolyzing activity as a measure of the
stability of 3D8 scFv because this activity is considered to mediate
the anti-viral activity of 3D8 scFv.
To increase its efﬁcacy as an anti-viral agent, 3D8 scFv has been
loaded in a nanoparticle and used for the generations of a
recombinant microorganism. When 3D8 scFv was loaded in poly
[lactic-co-glycolic acid] nanoparticles (3D8-PLGA NPs), it was
taken into cells much more effectively than free 3D8 scFv and
exhibited more sustained anti-viral activity against vesicular
stomatitis virus in vitro (Joung et al., 2012). In mice, Lactobacillus
engineered to secrete 3D8 scFv prevented infection with gastroin-
testinal murine norovirus when administered orally (Hoang et al.,
2015). It is thought that chromosomal DNA of this engineered
Lactobacillus is not susceptible to hydrolyzing activity of 3D8 scFv
because signal peptide-bearing 3D8 scFv encoded in the expres-
sion vector leads by default to the release of 3D8 scFv into
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somal DNA. In view of these, application of 3D8 scFv as an anti-viral
agent against a broad spectrum of viral infections is likely possible
in a wide variety of conditions. Therefore, knowledge of the
stability of 3D8 scFv in various biochemical and physical environ-
ments is important for the development of stable formulations and
speciﬁc delivery strategies.
The thermal stability of 3D8 scFv shown in Fig. 1A deviates little
from those of other scFvs. Although the analytical methods and
conditions were different, scFvs appeared to be less resistant to
thermal stress compared with many whole immunoglobulin
antibodies that may not melt completely at temperatures above
70 C (Wang et al., 2007). K1 scFv has a half-life of only 4 h at 37 C
(Chowdhury and Vasmatzis, 2003), and anti-c-Met scFv retained
only 20% activity after 2 h at 40 C (Edwardraja et al., 2011).
Approximately 95% of MOC31 scFv was found to undergo
precipitation after incubation for 30 min at 37 C and was
completely inactive after overnight incubation in human serum
at 37 C (Willuda et al., 1999). Finally, the denaturation tempera-
ture of A48 scFv was observed to be 63.2 C (Worn and Pluckthun,
1999).
Many scFvs are less stable than whole IgG or the Fab fragment
due to their propensity to become aggregated (Kramer et al., 2002;
Raag and Whitlow, 1995; Rothlisberger et al., 2005; Willuda et al.,
1999). The cause of this phenomenon could be the intrinsic
structural instability of the VH and VL domains derived from the
inherent primary structures, as well as the weak non-covalent
interaction between the VH and VL domains. Rational and
evolutional strategies to improve the biochemical and physical
stability of scFvs have been reported. Rational means include
substitution of potentially problematic residues that either reduce
the VH–VL interaction and/or cause aggregation, introduction of
disulﬁde bonds between the VH and VL domains, and grafting of
CDRs to a stable framework. Evolutional means include selection
by display techniques and selection under denaturing and/or
reducing conditions (Brockmann et al., 2005; Edwardraja et al.,
2011; Worn and Pluckthun, 2001). Indeed, the thermal stability of
many scFvs was noticeably improved by these techniques (Borras
et al., 2010; Chowdhury and Vasmatzis, 2003; Edwardraja et al.,
2011; Willuda et al., 1999; Worn and Pluckthun, 1999). These
strategies can also be applied to improve the thermal stability of
3D8 scFv. In addition to the intrinsic instability of scFvs, extrinsic
factors that are derived from the environment, such as pH,
temperature, buffering agents, ionic strength, surfactants, and
excipients can affect the stability of scFvs. Moreover, stability is
collectively determined by these factors (Paborji et al., 1994; Wang
et al., 2007). Although we focused on the effect of pH and
temperature on the functional stability of 3D8 scFv, each of these
extrinsic factors must be considered and optimized for pharma-
ceutical application of 3D8 scFv, as it will undergo various
processes during the formulation that could cause structural
and functional changes.
Functional instability of 3D8 scFv may result from factors such
as deamidation, aspartate isomerization, oxidation of methionine
and tryptophan residues, the presence of free-cysteine thiol
groups, the isoelectric point, and/or changes to the physical
stability induced by conformational changes and aggregation.
Although we did not establish the exact cause of functional
instability, it appears that the functional instability at elevated
temperatures (>50 C) is due to the unfolding and aggregation of
3D8 scFv rather than degradation, whereas decreased functional
stability at unfavorable pHs (<pH 3 and >pH 9) is due to unfolding,
aggregation, and degradation (Figs. 1 and 3). On the other hand,
anti-HBsAg scFv has been observed to maintain biological activity
at pH 7.1–9.3, but exists in an unfolded (denatured) state as well as
in an aggregated form above pH 11 (Pedroso et al., 2002).Interestingly, 3D8 scFv showed a broad range of optimal pH
conditions (pH 7–11) for DNA binding and DNA hydrolysis,
reaching a peak at pH 10 (Fig. 2). Furthermore, 3D8 scFv was
functionally stable at pH 3–10 and 37 C for up to 3 days, although a
reduction in stability was detected at pH 3 and pH 9–10 (Fig. 3).
This ﬁnding supports those of the previous study in which
3D8 scFv secreted by transgenic Lactobacillus was suggested to be
functionally active, resulting in protection from gastrointestinal
infection (Hoang et al., 2015) in the weak acidic pH of the intestine
(McConnell et al., 2008).
The DNA-hydrolyzing activity of 3D8 scFv was not affected by
the presence of the reducing agent DTT (Fig. 6), demonstrating that
3D8 scFv retains activity without intradomain disulﬁde bonds. This
is consistent with our previous report that 3D8 scFv displays
nucleic acid-hydrolyzing activity in the cytosol, which is a reducing
environment (Jang et al., 2009). This property is functionally
advantageous and allows 3D8 scFv to act as an “intrabody”, that is,
as an antibody that works inside the cell to bind to an intracellular
target (Cochet et al., 1998). Taking into account the mechanism of
the anti-viral effect of 3D8 scFv in inhibiting viral replication by
cleaving the genome and/or transcripts of invading viruses in the
cell cytosol after endocytosis (Jun et al., 2010), our ﬁndings support
a role for 3D8 scFv as a kind of “intrabody”. In the cytoplasm, the
intradomain disulﬁde bonds in scFvs cannot be formed, and many
scFvs are unstable and expressed at low levels, resulting in protein
aggregation and degradation in many cases (Guglielmi et al., 2011).
Therefore, the antibodies used for intracellular applications as
intrabodies need to have high stability in reducing conditions, and
many methods to select these antibodies have been developed
(Guglielmi et al., 2011; Martineau et al., 1998). In this context,
3D8 scFv has considerable practical potential as an intrabody.
5. Conclusion
Our study provides an understanding of the factors that
inﬂuence the enzymatic stability of the catalytic antibody
3D8 scFv in various biochemical and physical environments.
Based on its enzymatic stability, 3D8 scFv holds good potential for
development as an anti-viral therapeutic.
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